Crucell Announces PER.C6 Commercial Licensing Agreement with ADImmune Corporation
Advertisement
Crucell N.V. announced that it has signed a non-exclusive PER.C6® commercial license agreement with the Taiwan-based vaccine company ADImmune Corporation. ADImmune intends to use the PER.C6® cell line technology to develop and commercialize a vaccine against Japanese encephalitis virus in Taiwan and China.
Under the terms of the agreement, ADImmune will pay a license issuance fee, annual maintenance fees and royalties on future product sales. Further financial details were not disclosed.